Silverarc Capital Management as of Sept. 30, 2021
Portfolio Holdings for Silverarc Capital Management
Silverarc Capital Management holds 81 positions in its portfolio as reported in the September 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Biohaven Pharmaceutical Holding | 4.9 | $8.6M | 62k | 138.91 | |
| Veracyte (VCYT) | 4.7 | $8.3M | 180k | 46.45 | |
| Mirati Therapeutics | 4.6 | $8.1M | 46k | 176.90 | |
| Merus N V (MRUS) | 4.3 | $7.6M | 346k | 22.00 | |
| Amryt Pharma Sponsored Ads | 3.5 | $6.2M | 516k | 12.05 | |
| Horizon Therapeutics Pub L SHS | 3.2 | $5.7M | 53k | 109.53 | |
| Cogent Biosciences (COGT) | 3.2 | $5.7M | 678k | 8.41 | |
| Immatics SHS (IMTX) | 3.2 | $5.7M | 438k | 13.00 | |
| Fulcrum Therapeutics (FULC) | 3.0 | $5.2M | 186k | 28.21 | |
| Nextcure (NXTC) | 2.7 | $4.9M | 721k | 6.74 | |
| Insmed Com Par $.01 (INSM) | 2.7 | $4.8M | 175k | 27.54 | |
| Research Alliance Corp Ii Com Cl A | 2.6 | $4.7M | 473k | 9.85 | |
| United Therapeutics Corporation (UTHR) | 2.2 | $3.9M | 21k | 184.58 | |
| Intra Cellular Therapies (ITCI) | 2.1 | $3.8M | 102k | 37.28 | |
| Cerus Corporation (CERS) | 2.1 | $3.8M | 619k | 6.09 | |
| ImmunoGen | 2.1 | $3.7M | 650k | 5.67 | |
| Sierra Oncology Com New | 2.0 | $3.6M | 164k | 21.92 | |
| Morphic Hldg (MORF) | 1.8 | $3.3M | 58k | 56.63 | |
| Iteos Therapeutics (ITOS) | 1.8 | $3.2M | 117k | 27.00 | |
| Aclaris Therapeutics (ACRS) | 1.8 | $3.1M | 173k | 18.00 | |
| Arvinas Ord (ARVN) | 1.7 | $3.1M | 37k | 82.18 | |
| Compugen Ord (CGEN) | 1.5 | $2.7M | 452k | 5.97 | |
| Leap Therapeutics | 1.4 | $2.5M | 620k | 4.01 | |
| Halozyme Therapeutics (HALO) | 1.4 | $2.4M | 60k | 40.68 | |
| Chemocentryx Put Option | 1.3 | $2.4M | 139k | 17.10 | |
| Bellus Health Com New | 1.3 | $2.2M | 365k | 6.14 | |
| Helix Acquisition Corp Com Cl A | 1.3 | $2.2M | 224k | 9.93 | |
| Celldex Therapeutics Com New (CLDX) | 1.2 | $2.1M | 38k | 54.00 | |
| Eloxx Pharmaceuticals | 1.2 | $2.1M | 1.3M | 1.63 | |
| Cyclacel Pharmaceuticals | 1.2 | $2.0M | 389k | 5.27 | |
| Seagen | 1.1 | $2.0M | 12k | 169.80 | |
| Erasca (ERAS) | 1.1 | $2.0M | 93k | 21.22 | |
| Otonomy | 1.1 | $2.0M | 1.0M | 1.92 | |
| Vistagen Therapeutics Com New | 1.1 | $1.9M | 708k | 2.74 | |
| Seres Therapeutics (MCRB) | 1.1 | $1.9M | 275k | 6.96 | |
| Benitec Biopharma | 1.0 | $1.8M | 498k | 3.57 | |
| Cytokinetics Com New (CYTK) | 1.0 | $1.8M | 49k | 35.73 | |
| Miragen Therapeutics (VRDN) | 1.0 | $1.7M | 106k | 16.45 | |
| Lucira Health | 0.9 | $1.7M | 221k | 7.60 | |
| Zentalis Pharmaceuticals (ZNTL) | 0.9 | $1.6M | 24k | 66.65 | |
| Stereotaxis Com New (STXS) | 0.9 | $1.6M | 292k | 5.38 | |
| Jounce Therapeutics | 0.9 | $1.5M | 209k | 7.43 | |
| Polypid SHS | 0.8 | $1.4M | 183k | 7.78 | |
| Adamas Pharmaceuticals | 0.8 | $1.4M | 288k | 4.91 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.8 | $1.3M | 129k | 10.42 | |
| Viewray (VRAYQ) | 0.8 | $1.3M | 185k | 7.21 | |
| Deciphera Pharmaceuticals (DCPH) | 0.7 | $1.3M | 37k | 33.99 | |
| Biogen Idec (BIIB) | 0.7 | $1.2M | 4.4k | 282.98 | |
| Arena Pharmaceuticals Com New | 0.6 | $1.1M | 19k | 59.52 | |
| Medicus Sciences Acquisition Cl A Shs | 0.6 | $1.1M | 110k | 9.75 | |
| Kura Oncology (KURA) | 0.6 | $1.1M | 57k | 18.72 | |
| Social Cap Suvretta Hlds Crp Class A Ord Shs | 0.6 | $1.1M | 106k | 9.95 | |
| Social Cap Suvretta Hlds Crp Class A Ord Shs | 0.6 | $1.0M | 106k | 9.88 | |
| Social Cap Suvretta Hlds Cp Class A Ord Shs | 0.6 | $1.0M | 106k | 9.81 | |
| Crinetics Pharmaceuticals In (CRNX) | 0.6 | $1.0M | 49k | 21.04 | |
| Social Cap Suvretta Hld Crpi Class A Ord Shs | 0.6 | $1.0M | 106k | 9.80 | |
| Athira Pharma (ATHA) | 0.6 | $998k | 106k | 9.38 | |
| Mereo Biopharma Group Ads (MREO) | 0.5 | $885k | 366k | 2.42 | |
| Renalytix Ads (RNLX) | 0.4 | $742k | 37k | 20.05 | |
| Intellia Therapeutics (NTLA) | 0.4 | $664k | 5.0k | 134.14 | |
| Evogene SHS (EVGN) | 0.4 | $656k | 248k | 2.64 | |
| Dicerna Pharmaceuticals | 0.4 | $626k | 31k | 20.17 | |
| Point Biopharma Global | 0.3 | $552k | 72k | 7.70 | |
| Cybin Ord (CYBN) | 0.3 | $549k | 250k | 2.20 | |
| Guardant Health (GH) | 0.3 | $527k | 4.2k | 124.94 | |
| Cabaletta Bio (CABA) | 0.3 | $511k | 42k | 12.16 | |
| Iveric Bio | 0.3 | $487k | 30k | 16.23 | |
| Curis Com New | 0.3 | $486k | 62k | 7.83 | |
| Ayala Pharmaceuticals Incorporated | 0.3 | $464k | 41k | 11.33 | |
| Evelo Biosciences Put Option | 0.2 | $434k | 62k | 7.03 | |
| Calithera Biosciences | 0.2 | $406k | 186k | 2.18 | |
| Keros Therapeutics (KROS) | 0.2 | $396k | 10k | 39.60 | |
| Surface Oncology | 0.2 | $379k | 50k | 7.58 | |
| Rapt Therapeutics (RAPT) | 0.2 | $366k | 12k | 31.03 | |
| Xenon Pharmaceuticals (XENE) | 0.2 | $297k | 19k | 15.28 | |
| Arcturus Therapeutics Hldg I (ARCT) | 0.2 | $297k | 6.2k | 47.84 | |
| Affimed Therapeutics B V | 0.2 | $292k | 47k | 6.19 | |
| Adagio Therapeutics (IVVD) | 0.1 | $211k | 5.0k | 42.20 | |
| Renovacor *w Exp 99/99/999 | 0.0 | $42k | 105k | 0.40 | |
| Catalyst Biosciences Com New | 0.0 | $41k | 10k | 4.10 | |
| Medicus Sciences Acquisition *w Exp 02/12/202 | 0.0 | $35k | 50k | 0.70 |
